Device Trial Radar · NCT03900468
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
29
Actual
Start
Mar 5, 2020
Primary completion
Oct 15, 2025
Study completion Feb 26, 2026
Sponsor
- Lead sponsor
- MedtronicNeuroNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Conditions
- Epilepsy
Interventions
Activa™ PC and Percept™ PC Neurostimulation SystemsDevice
Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Reduction in Total Seizure FrequencyTime frame: Pre-implant compared to 36 months post-implant
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA)
Los Angeles, California
University of California San Francisco UCSF Medical Center
San Francisco, California
Emory University Hospital
Atlanta, Georgia
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.